Valve-in-Valve TAVR vs. Repeat Surgery for Aortic Bioprosthesis Failure

Compared with surgery, transcatheter aortic-valve replacement offered better short-term and similar medium-term outcomes.

Interventionalists increasingly use transcatheter aortic-valve replacement (TAVR) for valve-in-valve (VIV) treatment of a failing surgical bioprosthesis. However, long-term outcomes with this procedure and data on patients at low and intermediate risk for surgery are not known. To compare VIV TAVR with repeat (redo) surgery, investigators relied on a French administrative database of hospital discharges and used propensity-score matching to identify 717 matched pairs of patients who had undergone VIV TAVR or redo surgery between 2010 and 2019.

At 30 days, all-cause mortality was 3.6% with VIV TAVR and 7.3% with redo surgery (OR, 0.48). The two groups had similar rates of stroke, myocardial infarction (MI), and major bleeding, although new at…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)